Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2007 1
2008 2
2009 1
2010 1
2011 4
2012 5
2013 7
2014 2
2018 1
2019 4
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The red blood cell in vascular occlusion.
Yedgar S, Koshkaryev A, Barshtein G. Yedgar S, et al. Among authors: koshkaryev a. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):263-8. doi: 10.1159/000073578. Pathophysiol Haemost Thromb. 2002. PMID: 13679654 Free article. Review.
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Kamoun WS, et al. Among authors: koshkaryev a. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5. Nat Biomed Eng. 2019. PMID: 30952988
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Kamoun W, et al. Among authors: koshkaryev a. Pharmaceutics. 2020 Oct 20;12(10):996. doi: 10.3390/pharmaceutics12100996. Pharmaceutics. 2020. PMID: 33092175 Free PMC article.
Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.
Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A. Tam EM, et al. Among authors: koshkaryev a. Sci Transl Med. 2019 Oct 2;11(512):eaax0720. doi: 10.1126/scitranslmed.aax0720. Sci Transl Med. 2019. PMID: 31578241
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models.
Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ. Kamoun WS, et al. Among authors: koshkaryev a. Mol Cancer Ther. 2020 Jan;19(1):270-281. doi: 10.1158/1535-7163.MCT-19-0414. Epub 2019 Oct 9. Mol Cancer Ther. 2020. PMID: 31597714
26 results